Results 131 to 140 of about 1,018,202 (279)

Brain metastases from colorectal cancer - a retrospective dual center study. [PDF]

J Neurooncol
Müller S, Hendricks A, Uttinger K, Kostatin M, Brüggemann M, Schrader M, Polat B, Flemming S, Lock JF, Germer CT, Wiegering A, Pession U.   +11 more
europepmc   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Safety of Simultaneous Robot-Assisted Resection of Colorectal Malignancy and Synchronous Liver Metastases. [PDF]

J Clin Med
Petrič M, Plešnik B, Košir JA, Trotovšek B, Grosek J.   +4 more
europepmc   +1 more source

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study

Neuro-Oncology, 2017
D. Cagney, Allison M. Martin, P. Catalano, A. Redig, N. Lin, E. Lee, P. Wen, I. Dunn, W. Bi, S. Weiss, D. Haas-Kogan, B. Alexander, A. Aizer   +12 more
semanticscholar   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)

JAMA Oncology, 2017
P. Sperduto, T. Yang, K. Beal, Hubert Y. Pan, P. Brown, A. Bangdiwala, R. Shanley, Norman Yeh, L. Gaspar, S. Braunstein, P. Sneed, J. Boyle, J. Kirkpatrick, K. Mak, H. Shih, A. Engelman, D. Roberge, Nils D. Arvold, B. Alexander, M. Awad, J. Contessa, V. Chiang, J. Hardie, D. Ma, E. Lou, W. Sperduto, M. Mehta   +26 more
semanticscholar   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Spread Through Air Spaces in Colorectal Lung Metastases Signals Local Recurrenece and Reflects Morphologic Aggressiveness of the Primary Tumor. [PDF]

Pathol Int
Nakai T, Morita S, Kurebayashi Y, Monno M, Seishima R, Shigeta K, Okabayashi K, Mino-Kenudson M, Kitagawa Y, Asakura K.   +9 more
europepmc   +1 more source

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

The Lancet Oncology, 2017
M. Davies, P. Saiag, C. Robert, J. Grob, K. Flaherty, A. Arance, V. Chiarion-Sileni, L. Thomas, T. Lesimple, L. Mortier, S. Moschos, D. Hogg, I. Márquez-Rodas, M. Del Vecchio, C. Lebbé, N. Meyer, Ying Zhang, Yingjie Huang, B. Mookerjee, G. Long   +19 more
semanticscholar   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source